Supreme Court Bans Stem Cell Therapy for Autism Outside Clinical Trials, Declares Practice Medical Malpractice
Key Insights
The Supreme Court of India (search) ruled that stem cell therapy for Autism Spectrum Disorder (search) outside approved clinical trials is unethical and constitutes medical malpractice due to lack of scientific evidence.
Justices declared that every use of stem cells (search) in patients outside approved clinical trials violates medical standards and fails to meet reasonable care requirements.
The court directed the Ministry of Health to provide solutions for patients currently receiving therapy while prohibiting commercial stem cell treatments for autism.
The Supreme Court of India (search) has issued a landmark ruling declaring that stem cell therapy for Autism Spectrum Disorder (search) (ASD (search)) administered outside approved and monitored clinical trials constitutes medical malpractice and is unethical. The decision, delivered by Justices J B Pardiwala and R Mahadevan, addresses widespread concerns over the commercial promotion and administration of unproven stem cell treatments across the country.
Court Declares Stem Cell Therapy Medical Malpractice
The bench stated unequivocally that "every use of stem cells (search) in patients outside an approved clinical trial is unethical and shall be considered as malpractice." The court emphasized that such interventions lack scientific evidence and breach established medical standards, making them unsuitable for routine clinical practice.
The justices ruled that medical practitioners offering stem cell therapy as routine care fail to meet reasonable standards of patient care. According to the judgment, a medical practitioner "cannot be said to meet the standard of reasonable care if he administers an intervention that lacks credible scientific evidence of safety and efficacy or where authoritative medical bodies unequivocally state that such a form of treatment is not recommended."
Regulatory Framework and Patient Protection
The Supreme Court's decision came in response to a writ petition filed by Yash Charitable Trust (search) and others, which raised concerns about the rampant promotion and administration of stem cell therapy for ASD (search) by clinics nationwide. The petitioners alleged that despite stem cell therapy remaining experimental, it was being advertised and offered as a "treatment" or "cure" for ASD in violation of existing laws.
The court rejected arguments that stem cell therapy was legally permissible under drug laws, clarifying that "although the stem cells (search) administered for therapeutic use in ASD (search) are characterised as drugs under the Drugs Act, 1940, the same by itself is not determinative" of their permissibility as a clinical service.
Transition Plan for Current Patients
Recognizing the potential impact on patients currently receiving stem cell therapy, the court provided a measured approach to implementation. The bench stated it "does not wish to leave patients who are already undergoing the therapy in any apprehension that discontinuing the same may prove to be detrimental to their well-being."
The court directed the Secretary of the Ministry of Health and Family Welfare, in consultation with AIIMS officials and the National Medical Council (search), to "provide the best possible solution in this regard to ensure that such patients are able to continue receiving the therapy till the time they can be re-routed to the institutions that are conducting clinical trials."
Patient Autonomy and Informed Consent
Addressing the issue of patient autonomy, the court ruled that "a treatment cannot be demanded by a patient as a matter of right." The justices determined that even voluntary patient consent does not constitute valid consent for unproven treatments due to the "lack of adequate information to form its basis."
However, the court clarified that patients retain "the liberty to participate in an approved and regulated research/clinical trial involving stem cell therapy for ASD (search)."
Regulatory Enforcement and Legal Framework
The Supreme Court highlighted significant shortfalls in the current regulatory mechanism for stem cell research, noting that "the legal framework pertaining to stem cell research is fragmented and spread out across legislation with little harmony." This fragmentation makes "both compliance and enforcement an uphill task" and enables manipulation of patient vulnerabilities by errant practitioners.
The court directed that action must be taken against errant clinics under Section 32 and Section 40 of the Clinical Establishments (Registration and Regulation) Act, 2010, which provide for cancellation of registration and penalties.
Recommendations for Reform
The bench suggested comprehensive reforms to address regulatory gaps, including consolidation of rules, regulations, and guidelines governing stem cell-based clinical trials and research. Key recommendations included clearly defining stem cells (search) and their derivatives and establishing specific procedures for clinical trial applications.
The court recommended reconstituting the National Apex Committee for Stem Cell Research & Therapy (search) (NAC-SCRT) to ensure proper monitoring and regulation of stem cell research. The justices criticized the Centre for allowing the situation to worsen "without any suitable and timely intervention," leading to parents seeking unproven treatments while incurring significant financial costs.
The court noted that various clinics continued to recommend and perform stem cell therapy as routine clinical treatment for ASD (search) "in flagrant violation of the aforesaid statutory mandate" due to lack of executive action. The matter has been posted for review after four weeks, with the court urging the Centre to consolidate and clarify the legal position for better implementation.